FAKHRAVAC
Sign in to saveFAKHRAVAC () is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.
In the Vinony graph
Vinony's link graph records 1,281 inbound references to FAKHRAVAC, and connects out to SARS-CoV-2, Gam-COVID-Vac and COVID-19 pandemic in Italy.
It is catalogued under topics including Chemical articles without CAS registry number, Chemical pages without ChemSpiderID and Chemical pages without DrugBank identifier.
Vinony links it to 8 Wikipedia language editions.
Wikidata facts
- Subclass of
- inactivated vaccine
- Country of origin
- Iran
- Image
- FakhraVac vaccine 01 (cropped).jpg
Show 4 more facts
- vaccine for
- COVID-19
- Commons category
- FakhraVac vaccine
- legal status (medicine)
- medical emergency
- route of administration
- intramuscular injection
via Wikidata · CC0
~2 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Pharmacology
- Manufacturing
- Clinical trials
- Authorizations
- See also
- References
FAKHRAVAC () is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh. According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran. Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.
Excerpted from Wikipedia’s “FAKHRAVAC” article, available under the CC BY-SA 4.0 licence.